ESTRO 2022 - Abstract Book

S465

Abstract book

ESTRO 2022

prescription point and dose, the involvement of various professional groups, available alternative treatments, OAR constraints, the use of dummy applicators, sterilisation practice, plaque placement verification, guidelines and outcome data collection. The physicist survey includes questions on measurements of plaque activity, depth dose and profiles, TPS commissioning, planning methodology, radiobiological corrections, independent checks and guidelines. The survey will be launched in February 2022. We hope to get responses from a high proportion of Ruthenium clinics. We aim to publish the data, though clinic names will be kept confidential.

Conclusion

A clinician and a physicist survey have been created with the aim to collect data about the current clinical practice of the use of Ruthenium-106.

SP-0527 Clinical management and treatment outcomes of eye plaque treatment of uveal melanoma

B. Fionda

Italy Abstract not available

Debate: This house believes that in 10 years particle therapy will be in a better place than now!

SP-0529 For the motion - Protons for Protons

T. Bortfeld

USA Abstract not available

SP-0530 Against the motion - Photons against Protons

M. Guckenberger

Switzerland Abstract not available

SP-0531 For the motion (rebuttal) - Photons for Protons

M. Aznar 1

United Kingdom Abstract not available

SP-0532 Against the motion (rebuttal) - Protons against Protons

E. Troost 1

1 Faculty of Medicine and University Hospital Carl Gustav Carus, Radiotherapy and Radiation Oncology, Dresden, Germany

Abstract Text "This house believes that in 10 years particle therapy will be in a better place than now!". This is quite a broad statement leaving plenty of room for arguments supportive of and against the motion. Why will it take 10 years and not 5? With the increasing number of (randomised) clinical studies or prospective registries on treatment outcome including the model- based approach, I believe data supportive of particle therapy will be available at an earlier point in time. The European Particle Therapy Network is a taskforce of ESTRO aimed at generating evidence asap by combining the outcome data of European particle centres. Why in a better place? In the past, particle sites were often research institutes turned into clinical treatment facilities. But nowadays, compact particle facilities are being integrated into clinical departments, in which protons or particles are then offered along with modern photon techniques. Therefore, the use of particles is already moving amidst our armada of therapeutic options. However, indeed, some developments will take more than 5 years before reaching the status of clinical implementation, e.g., MR-integrated proton therapy as well as upright solutions. I am convinced that some of those will revolutionise the field of particle therapy by expanding the clinical applications, altering fractionation schedules and, hopefully, real-time visualisation of the particle beam during the phase of dose delivery.

Joint Symposium: ESTRO-ISMRM: Quantitative MRI for radiation oncology